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ABSTRACT
Epidemiological and experimental data point to involvement of oxygen derived radicals in the pathogenesis of gyne-
cological disorders, as well as in cancer development. The objective of the present study was to examine changes in
activities and levels of copper/zinc superoxide dismutase (CuZnSOD) and lipid hydroperoxides (LOOH) in blood and
endometrial tissue of patients diagnosed with uterine myoma, endometrial polypus, hyperplasia simplex, hyperplasia
complex and adenocarcinoma endometrii. The results of our study have shown decreased SOD activities and unchanged
SOD protein level in blood of all examined patients in comparison to healthy subjects. Decrease of both SOD activity
and level was found in endometrium of patients with hyperplasia simplex, hyperplasia complex and adenocarcinoma in
comparison to women with polypus or myoma. LOOH level was elevated in both tissues of patients with hyperplasia
or adenocarcinoma in comparison to healthy subjects or patients with benign diagnosis. Our findings suggest that the
decrease in SOD activity and level, as well as the increase in LOOH level, in patients with gynecological disorders,
render these patients more susceptible to oxidative damage caused by reactive oxygen species (ROS). An imbalance in
ROS formation and SOD level may be important in the pathogenesis and/or perpetuation of tissue damage in gyneco-
logical patients. Since evidence suggests that SOD may be a therapy target for cancer treatment, our findings provide
a basis for further research and options for clinical applications.
Key words: copper/zinc superoxide dismutase, lipid hydroperoxides, uterine myoma, endometrial polypus, endome-
trial hyperplasia, endometrial adenocarcinoma.
INTRODUCTION
Reactive oxygen species (ROS), such as superoxide
(O∙−2 ) and hydrogen peroxide (H2O2), are produced inmetabolic processes. A balance between O∙−2 productionand elimination is important for maintenance of a proper
Correspondence to: Dr. Snežana Pejic´E-mail: snezana@vin.bg.ac.yu
redox state in the cell (Dröge 2002). Under physiolog-
ical conditions, ROS generation, including lipid perox-
idation (LPO), is counterbalanced by the action of an-
tioxidant enzymes (AOE) such as superoxide dismutases
(SODs), cytosolic copper/zinc SOD (CuZnSOD) and mi-
tochondrial manganese SOD (MnSOD), catalase (CAT),
and various glutathione peroxidases (GPx) (Zelko et al.
2002, Brigelius-Flohé 2006). It is also well known that
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ROS participate in the pathogenesis of various diseases
including carcinogenesis (Valko et al. 2007).
Endometrial carcinoma is the most frequently diag-
nosed malignancy of the female genital tract. It is often
preceded by histopathologic lesions known as endome-
trial hyperplasia (Mutter 2002), and it is generally con-
sidered a precursor of endometrial cancer (Münstedt et
al. 2004). According to the current World Health Orga-
nization (WHO) nomenclature, endometrial hyperplasia
is classified in four categories, simple hyperplasia (SH),
complex hyperplasia (CH), simple atypical hyperplasia
(SAH) and complex atypical hyperplasia (CAH).
In recent years, there has been a growing interest
in the investigation on the role played by ROS and anti-
oxidants in gynecological patients. Chiou and Hu (1999)
reported on the elevated LPO and decreased plasma and
erythrocytes SOD activity in both uterine cervicitis and
myoma patients, while activities of CAT and GPx were
elevated in cervicitis patients and lowered in myoma
patients. Similar observations were made on erythro-
cytes SOD, CAT and GPx activities of cervicitis patients,
whereas activities of examined enzymes decreased in
cervical cancer patients (Manoharan et al. 2004). LPO
was found to be increased in both groups of patients
(Manoharan et al. 2004). In endometrial cancer tis-
sue of both Finnish and Japanese women, the activity of
SOD was found to be significantly lower than in normal
endometrium (Punnonen et al. 1993). Our recent re-
sults showed that SOD activity was lower in the blood
of patients with uterine polypus or myoma, hyperplasia
endometrii and adenocarcinoma endometrii than in that
of healthy subjects (Pejic´ et al. 2006). There is a limited
amount of information regarding the relative levels of
SOD expression in gynecological patients. It was shown
that levels of both CuZnSOD and MnSOD in endome-
triosis and adenomyosis were persistently higher than
their respective levels throughout the menstrual cycle in
fertile controls (Ota et al. 1999). Increase in SOD level
has also been observed in ovarian cancer patients (Hu
et al. 2005). Other studies showed that SOD levels in
various cancer tissues were unchanged or lower than in
normal tissue (Bostwick et al. 2000, Monari et al. 2006).
The aim of this study was to investigate changes
in CuZnSOD activities and protein levels, as well as
LPO level in blood and endometrial tissue of patients
diagnosed with uterine myoma, endometrial polypus,
hyperplasia simplex, hyperplasia complex and adeno-
carcinoma endometrii.
MATERIALS AND METHODS
SUBJECTS
The material used in this study comprised 103 blood
samples and 88 tissue specimens of women admitted to
the Department of Gynecology and Obstetrics for gy-
necological evaluation within routine checkups or for
abnormal uterine bleeding. The specimens were taken
after obtaining informed consent and the study was con-
ducted prospectively. The protocol followed is consis-
tent with the World Medical Association Declaration of
Helsinki (Ethical Principles for Medical Research In-
volving Human Subjects).
On the basis of diagnosis and histological exami-
nation, subjects were divided into the following groups:
healthy control patients (C, n = 15, mean ± SEM: 49 ±
3 yr); patients with benign uterine changes: polypus en-
dometrii (PE, n = 18, 45 ± 3 yr) or uterus myomato-
sus (UM, n = 12, 47 ± 2 yr); patients with abnormal
bleeding: hyperplasia simplex endometrii (SH, n = 31,
48±1 yr), hyperplasia complex endometrii (CH, n= 22,
48± 2 yr) or adenocarcinoma endometrii, stage I (ACE,
n = 5, 59± 3 yr).
SAMPLES
Venous blood samples were collected into heparinized
tubes on the same day of endometrial biopsy and ali-
quoted immediately. For SOD assay (OxisResearchTM),
blood was centrifuged at 2500 g for 5 min. Plasma was
discarded and the pellet resuspended in 4 packed-cell vol-
ume of ice-cold demineralized ultrapure water (MilliQ
reagent grade water system, Millipore Corp., Bedford,
MA, USA). After the addition of ethanol/chloroform
extraction reagent (62.5/37.5 vol/vol) to remove hemo-
globin, samples were centrifuged at 3000 g for 10 min
(Eppendorf centrifuge 5417, Eppendorf AG, Hamburg,
Germany). The upper aqueous layer was collected and
stored at −70◦C until assay.
Endometrial tissue samples were washed in saline
solution and homogenized in phosphate buffer contain-
ing 0.05M KH2PO4 and 1 mM EDTA, pH 7.8 (1 g tissueper 2 ml buffer) in a Teflon/glass homogenizer (Spindler
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& Hoyer, Göttingen, Germany) and frozen at −70◦C
for 20 h to disrupt cell membranes. For SOD assay
(OxisResearchTM), thawed homogenates were vortexed
for 1 min and centrifuged at 8600 g, for 20 min at 4◦C
(Eppendorf centrifuge 5417, Eppendorf AG, Hamburg,
Germany). According to the manufacturer’s recommen-
dation, after addition of ethanol/chloroform extraction
reagent (62.5/37.5 vol/vol) to completely remove hemo-
globin, samples were centrifuged at 6000 g for 20 min
(Beckman centrifuge J2-21, Beckman Instruments Inc.,
Palo Alto, CA, USA). The upper aqueous layer was col-
lected and stored at −70◦C until assay. SOD assay was
performed spectrophotometrically (Perkin Elmer Spec-
trophotometer, Lambda 25, Perkin Elmer Instruments,
Norwalk, CT, USA). The specific enzyme activity was
expressed as Units (U) per milligram of total protein
(U/mg protein). Determination of protein concentration
was performed in crude hemolysates using the method
of Lowry et al. (1951) and expressed as mg/ml.
SOD ACTIVITY ASSAY
Determination of SOD activity was performed using
Oxis Bioxytechr SOD-525TM Assay (Oxis Interna-
tional, Inc., Portland, OR, USA). The method is based
on SOD-mediated increase of autoxidation of 5,6,6a11b-
tetrahydro-3,9,10-tryhydroxybenzo[c]fluorene in aque-
ous alkaline solution to yield a chromophore with max-
imum absorbance at 525 nm. The SOD activity is de-
termined from the ratio of the autoxidation rates in the
presence (Vs) and absence (Vc) of SOD. One SOD-525
activity unit is defined as the activity that doubles the
autoxidation rate of the blank control.
LIPID HYDROPEROXIDES
LOOH was measured by Oxis Bioxytechr LPO-560TM
Assay (Oxis International, Inc., Portland, OR, USA),
which is based on the oxidation of ferrous (Fe2+) ionsto ferric (Fe3+) ions by hydroperoxides, in acidic condi-tions. Ferric ions then bind to the indicator dye, xylenol
orange, yielding a colored complex. The absorbance of
the complex was measured at 560 nm. Since hydrogen
peroxide content in many biological samples is much
higher than that of other hydroperoxides, samples were
pretreated with catalase to decompose the existing H2O2and eliminate the interference. LOOH concentration was
expressed as nmol/mg protein.
WESTERN BLOTTING
Equal amounts of protein were dissolved in SDS-PAGE
sample loading buffer and electrophoresed in polyacry-
lamide gel (10%), according to Laemmli (1970). For
Western blotting, the proteins were transferred to ni-
trocellulose membranes. Non-specific binding sites on
membranes were blocked with TBST (10 mM Tris,
150 mM NaCl, 0.1% Tween 20) containing 1% BSA and
then probed with rabbit anti-CuZnSOD polyclonal an-
tibody (SOD-100, Stressgen Biotechnologies; 1:7500).
After the blots were washed, alkaline phosphatase-con-
jugated goat anti-rabbit IgG (SAB-301, Stressgen Bio-
technologies; 1:7500) was added. Each blot was trip-
licated and scanned. The density of bands was deter-
mined by ImageJ processing software and normalized to
the loading control.
STATISTICAL ANALYSIS
Statistical analysis was carried out using the Kruskal-
Wallis method, whereas significances were evaluated
by Mann-Whitney test (values marked with asterisk(s)
are significantly different from control: *p<0.05, **p<
0.01, ***p< 0.001) and Dunn’s test (values with dif-
ferent letter designations are significantly different,
p< 0.05). Spearman’s rank correlation coefficient was
used to investigate associations between lipid peroxida-
tion and SOD activities. Two-tailed p values are given
throughout. All data were analyzed using GraphPad
Prism 4 software.
RESULTS
Superoxide dismutase activity in blood is shown in Fig-
ure 1. The obtained values showed significant varia-
tion among the examined groups (H = 46.83, df = 5,
p< 0.001). The activity was 26% (p< 0.05) and 20%
(p> 0.05) lower in polypus and myoma patients, re-
spectively, than in controls. It was also significantly
decreased in patients suffering from hyperplasia sim-
plex (42%, p< 0.001), hyperplasia complex (45%, p<
0.001) and adenocarcinoma (53%, p< 0.01). A signifi-
cant difference between hyperplasia or adenocarcinoma
patients and those suffering from myoma was also ob-
served (p<0.05).
Compared to control group values, protein levels of
SOD in blood (Fig. 2) were not significantly changed
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Fig. 1 – CuZnSOD activity in the blood of control patients (C) and
patients diagnosed with: polypus endometrii (PE), uterus myomatosus
(UM), simple hyperplasia (SH), complex hyperplasia (CH) and ade-
nocarcinoma endometrii (ACE). Mean SOD activities (±SD) are rep-
resented by the box; medians are plotted inside the box; the whiskers
extend to the 5th and 95th percentiles. Values which are not desig-
nated by the same letter (a, b, c) are significantly different (p< 0.05).
Values marked with asterisk(s) are significantly different (*p< 0.05,
**p<0.01, ***p<0.001) than the control (Pejic´ et al. 2006).
in all examined patients (p> 0.05). Also, there were no
significant differences of SOD protein levels among the
patient groups (p>0.05).
In endometrium of the same patients (Fig. 3), SOD
activity was similar in polypus and myoma patients.
However, compared to subjects with benign endome-
trial changes (polypus and myoma), SOD activity was
significantly lower in patients suffering from hyperpla-
sia simplex (∼41%), hyperplasia complex (∼53%) and
adenocarcinoma (∼72%) (p<0.05).
Similarly, SOD protein levels were found to be sig-
nificantly decreased (p<0.05) in the endometrium of pa-
tients diagnosed with hyperplasia simplex (∼30%), hy-
perplasia complex (∼44%) and adenocarcinoma (∼54%),
compared to polypus or myoma subjects (Fig. 4).
LOOH level (Table I) showed significant variation
among the examined groups in blood plasma (H= 23.38,
df= 5, p<0.001) and endometrial tissue (H= 37.11, df
= 4, p<0.001). Compared to controls, moderate eleva-
tion of lipid hydroperoxides in plasma was observed in
patients diagnosed with polypus endometrii or uterine
myoma (4% and 27%, respectively, p> 0.05) whereas
it was significantly higher in both types of hyperplasia
(SH: 41%, CH: 52%, p < 0.001) and adenocarcinoma
(57%, p<0.01). Also, in patients with simple hyperpla-
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Fig. 2 – A. Relative protein contents. Example of Western blot im-
munoassay for CuZnSOD in blood of control patients (C) and patients
diagnosed with polypus endometrii (PE), uterus myomatosus (UM),
simple hyperplasia (SH), complex hyperplasia (CH) and adenocarci-
noma endometrii (ACE). B. Comparison of relative SOD protein con-
tents in the blood of control patients (C) and patients diagnosed with
polypus endometrii (PE), uterus myomatosus (UM), simple hyperpla-
sia (SH), complex hyperplasia (CH) and adenocarcinoma endometrii
(ACE). Values are expressed in arbitrary units (AU), as a percent of the
protein content in controls which is considered as 100% (mean±SEM).
sia, levels of LOOH were higher than in patients with
polypus (p<0.05).
LOOH level in endometrial tissue was significantly
increased in patients with simple or complex hyperpla-
sia (∼50%) and adenocarcinoma (∼100%), compared to
polypus or myoma subjects.
We found a negative correlation between the level
of lipid hydroperoxides and SOD activity in blood (r =
−0.33, p< 0.001) and endometrial tissue (r = −0.21,
p<0.05) of the examined patients.
DISCUSSION
The role of reactive oxygen species in the transformation
of a normal cell into a malignant one has been a major
focus of recent research. Free radicals have been impli-
cated in many disease processes including cancer, while
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TABLE ILOOH concentration in plasma and endometrial tissue of control patients (C) and patients diagnosed with:polypus endometrii (PE), uterus myomatosus (UM), simple hyperplasia (SH), complex hyperplasia (CH)and adenocarcinoma endometrii (ACE), (mean ± SD).
Parameters/Patients C PE UM SH CH ACE
Plasma LOOH 0.19± 0.02a 0.20± 0.09ac 0.24± 0.04ad* 0.27± 0.07bd*** 0.27± 0.07bcd*** 0.29± 0.04bcd**(nmol/mg protein)
Endometrial
tissue LOOH 0.22± 0.06a 0.24± 0.09a 0.33± 0.09b 0.34± 0.07b 0.47± 0.08b
(nmol/mg protein)
Values with different letter designations are significantly different (p<0.05). Values marked with asterisks are significantly different (*p<0.05,
**p<0.01, ***p<0.001) from the control.
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Fig. 3 – CuZnSOD activity in the endometrium of patients diagnosed
with: polypus endometrii (PE), uterus myomatosus (UM), simple hy-
perplasia (SH), complex hyperplasia (CH) and adenocarcinoma en-
dometrii (ACE). Mean SOD activities (±SD) are represented by the
box; medians are plotted inside the box; the whiskers extend to the 5th
and 95th percentiles. Values not designated by the same letter (a, b)
are significantly different (p <0.05).
superoxide dismutases are the main enzymes responsible
for the elimination of superoxide radicals and are con-
sidered to be key antioxidants in aerobic cells (Hileman
et al. 2001).
In the blood of the examined patients, SOD activi-
ties were decreased while SOD protein levels remained
stable in comparison to healthy subjects. Also, the de-
crease in SOD activity was more pronounced in women
with hyperplasia or adenocarcinoma than in those suf-
fering from polypus or myoma, while higher levels of
LOOH were recorded in all examined groups, in com-
parison to controls, except for patients with polypus en-
dometrii. These results are in accordance with findings
of other authors. Patients with cervicitis or myoma had
lower plasma SOD activity and elevated lipid peroxida-
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Fig. 4 – A. Relative protein contents. Example of Western blot im-
munoassay for CuZnSOD in the endometrium of patients diagnosed
with polypus endometrii (PE), uterus myomatosus (UM), simple hy-
perplasia (SH), complex hyperplasia (CH) and adenocarcinoma en-
dometrii (ACE). B. Comparison of relative SOD protein contents in
endometrium patients diagnosed with polypus endometrii (PE), uterus
myomatosus (UM), simple hyperplasia (SH), complex hyperplasia
(CH) and adenocarcinoma endometrii (ACE). Values are expressed in
arbitrary units (AU), as a percent of the protein content in PE patients
which is considered as 100% (mean±SEM). Values not designated by
the same letter (a, b) are significantly different (p <0.05).
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tion, compared to healthy women, whereas erythrocyte
SOD activity was significantly lower only in myoma pa-
tients (Chiou and Hu 1999). Decreased SOD activity and
enhanced lipid peroxidation were found in erythrocytes
of cervical cancer patients as well, compared to healthy
subjects and cervicitis patients (Manoharan et al. 2004).
A profound decrease in SOD activity and an in-
crease in lipid peroxidation were also found in endo-
metrium of patients with hyperplasia simplex, hyper-
plasia complex and adenocarcinoma, in comparison to
women with polypus or myoma. In adenocarcinoma
patients, we observed a more pronounced decrease in
SOD activity than in hyperplastic subjects. Levels of
SOD protein were found to be 30-45% lower in endo-
metrial tissue with hyperplasia or adenocarcinoma, com-
pared to polypus and myoma. Previous analysis of en-
dometrial samples from two different human popula-
tions (Japanese and Finnish women) showed signific-
antly decreased SOD activity and higher LPO in en-
dometrium of cancer patients than in the normal tis-
sue, which pointed to an impairment in the enzymic AO
defense system (Punnonen et al. 1993). Lower SOD
concentrations were recorded in the peritoneal fluid of
infertile women with endometriosis (Liu et al. 2001,
Szczepanska et al. 2003). Recent evidence also indi-
cates decreased SOD activity and expression in many
disease states or pathological conditions, including can-
cer (Bostwick et al. 2000, Cullen et al. 2003). Other
studies, however, showed that SOD levels or activities
in various tissues with neoplastic changes appeared un-
changed or elevated compared to normal tissues (Bala-
subramaniyan et al. 1994, Chung-man Ho et al. 2001,
Hu et al. 2005). Such observations are likely because of
the different assays and various cell types used in those
studies.
Decrease of enzyme activity could be a consequen-
ce of elevated endogenous ROS production, as indicated
by several studies. Kong et al. (2000) showed that, in
response to oxidative stress, SOD enzyme may be con-
sumed to prevent oxidative damage since it was shown
that the overproduction of ROS exhausts the SOD ca-
pacity. Similar observation was recorded by Onodera et
al. (2003) regarding the antioxidant defense system in
general. It was also shown that oxygen radical produc-
tion, which elevates lipid peroxidation, increases with
clinical progression of diseases (Bagchi and Puri 1998,
Skrzydlewska et al. 2005). In support of these observa-
tions, we found negative correlation between LOOH and
SOD activity in blood and endometrial tissue.
Evidence suggests that transformed tissues produce
high levels of ROS and are constantly under oxidative
stress (Hileman et al. 2001). The increase in ROS, such
as O−2 , is able to stimulate cell cycle progression andpromote cell proliferation. Although the precise mecha-
nisms responsible for such elevation of ROS are not yet
defined, several potential mechanisms have been sug-
gested. They include the oncogenic signals, such as c-
myc and Ras (Hu et al. 2005) or mitochondrial mu-
tations and respiratory chain malfunction, which may
lead to increased superoxide production (Pelicano et al.
2004). In addition, molecular mechanisms by which
the expression of cytosolic SOD responds to ROS stress,
have not been well characterized (Hu et al. 2005). De-
creased cytosolic SOD level in gynecological disorders,
observed in our study, may be due to a reduced expres-
sion of the SOD gene. Other possibilities include a di-
minished translation rate for SOD mRNA in endometrial
hyperplastic and carcinoma cells. Such a discrepancy in
mRNA levels and the levels of corresponding proteins,
suggesting possible translational regulation, has been re-
ported for many gene products in normal and malignant
cells (Klausner et al. 1993, Bommer et al. 2004, Lauer et
al. 1999). In addition, Brown et al. (2004) demonstrated
an essential role of O2 or O∙−2 in the posttranslational ac-tivation of CuZnSOD and in the ratio of active to inactive
CuZnSOD, which may be relevant to various diseases.
Most studies have shown both in vivo and in vitro
that antioxidant enzyme levels are altered in neoplastic
changes. One of the consequences of AO enzyme im-
balance is an alteration in cellular redox state (Oberley
2002). Cell damage caused by activated oxygen meta-
bolites and reduced antioxidant capacity might be re-
sponsible for certain characteristics of malignant cells
and biological differences between neoplastic and nor-
mal tissues (Oberley and Oberley 1997, Toyokuni 2006).
Lower SOD activity and expression, as well as increased
LOOH concentration, observed in our study, indicate that
patients with benign, and particularly with premalignant
and malignant gynecological diseases, are likely to be
under relatively high levels of oxidative stress.
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Recent findings show that SOD might be a promis-
ing therapeutic target for cancer treatment. Depending
on the cell type and the level of SOD activity, inhibition
or enhancement of SOD using molecular biology tech-
niques reflects two possible approaches to cancer ther-
apy. For the cells with lower SOD activity, enhancement
of SOD expression may be used to reverse the premalig-
nant and malignant phenotype (Hileman et al. 2001).
Our study shows that gynecological patients have
lower SOD activity in both blood and endometrium,
while the SOD protein level is decreased only in the en-
dometrial tissue. There is a possibility that women with
hyperplasia or adenocarcinoma are more susceptible to
oxidative stress since a more pronounced decrease of
SOD level was observed in those patients.
Further investigation is necessary to reveal if al-
terations of SOD may contribute to the understanding
of molecular mechanisms of carcinogenesis and to the
development of new therapeutic approaches in clinical
practice.
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RESUMO
Resultados epidemiológicos e experimentais apontam para o
envolvimento dos radicais derivados do oxigênio na patogê-
nese das moléstias ginecológicas, assim como no desenvolvi-
mento do câncer. O objetivo do presente estudo foi o de exa-
minar as alterações nas atividades e níveis de Cu/Zn superóxi-
do dismutase (CuZnSOD) e hidroperóxidos lipídicos (LOOH)
no sangue e tecido endometrial de pacientes diagnosticados
com mioma uterino, pólipo endometrial, hiperplasia simplex,
hiperplasia complex e adenocarcinoma do endométrio. Os re-
sultados de nosso estudo mostraram atividades de SOD dimi-
nuídas e nível de SOD proteína inalterado no sangue de todos
os pacientes examinados em comparação a indivíduos saudá-
veis. Diminuição de ambos, atividade de SOD e nível protéi-
co, foram encontrados no endométrio de pacientes com hiper-
plasia simplex, hiperplasia complex e adenocarcinoma em
comparação às mulheres com pólipos e/ou mioma. O nível
de LOOH estava elevado em ambos os tecidos de pacientes
com hyperplasia e adenocarcinoma em comparação a indiví-
duos saudáveis ou pacientes com diagnóstico benigno. Nossos
resultados sugerem que um decréscimo na atividade e nível pro-
téico de SOD, assim como um incremento no nível de LOOH,
em pacientes com desordens ginecológicas, tornam esses pa-
cientes mais susceptíveis ao dano oxidativo causado pelas espé-
cies reativas de oxigênio (ROS). Um desequilíbrio na formação
de ROS e no nível de SOD pode ser importante na patogênese
e/ou perpetuação do dano tecidual em pacientes ginecológicos.
Desde que existe evidência de que SOD pode ser um alvo para
terapia de câncer, nossos resultados fornecem uma base para
futura pesquisa e opções para aplicações clínicas.
Palavras-chave: Cu/Zn superóxido dismutase, hidroperóxi-
dos lipídicos, mioma uterino, pólipo endometrial, hiperplasia
endometrial, adenocarcinoma endometrial.
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